Cargando…
Calcium Phosphate Cements Combined with Blood as a Promising Tool for the Treatment of Bone Marrow Lesions
The solid phase of a commercial calcium phosphate (Graftys(®) HBS) was combined with ovine or human blood stabilized either with sodium citrate or sodium heparin. The presence of blood delayed the setting reaction of the cement by ca. 7–15 h, depending on the nature of the blood and blood stabilizer...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10143268/ https://www.ncbi.nlm.nih.gov/pubmed/37103294 http://dx.doi.org/10.3390/jfb14040204 |
_version_ | 1785033811315130368 |
---|---|
author | Limelette, Maxence De Fourmestraux, Claire Despas, Christelle Lafragette, Audrey Veziers, Joelle Le Guennec, Yohan Touzot-Jourde, Gwenola Lefevre, François-Xavier Verron, Elise Bouler, Jean-Michel Bujoli, Bruno Gauthier, Olivier |
author_facet | Limelette, Maxence De Fourmestraux, Claire Despas, Christelle Lafragette, Audrey Veziers, Joelle Le Guennec, Yohan Touzot-Jourde, Gwenola Lefevre, François-Xavier Verron, Elise Bouler, Jean-Michel Bujoli, Bruno Gauthier, Olivier |
author_sort | Limelette, Maxence |
collection | PubMed |
description | The solid phase of a commercial calcium phosphate (Graftys(®) HBS) was combined with ovine or human blood stabilized either with sodium citrate or sodium heparin. The presence of blood delayed the setting reaction of the cement by ca. 7–15 h, depending on the nature of the blood and blood stabilizer. This phenomenon was found to be directly related to the particle size of the HBS solid phase, since prolonged grinding of the latter resulted in a shortened setting time (10–30 min). Even though ca. 10 h were necessary for the HBS blood composite to harden, its cohesion right after injection was improved when compared to the HBS reference as well as its injectability. A fibrin-based material was gradually formed in the HBS blood composite to end-up, after ca. 100 h, with a dense 3D organic network present in the intergranular space, thus affecting the microstructure of the composite. Indeed, SEM analyses of polished cross-sections showed areas of low mineral density (over 10–20 µm) spread in the whole volume of the HBS blood composite. Most importantly, when the two cement formulations were injected in the tibial subchondral cancellous bone in a bone marrow lesion ovine model, quantitative SEM analyses showed a highly significant difference between the HBS reference versus its analogue combined with blood. After a 4-month implantation, histological analyses clearly showed that the HBS blood composite underwent high resorption (remaining cement: ca. 13.1 ± 7.3%) and new bone formation (newly formed bone: 41.8 ± 14.7%). This was in sharp contrast with the case of the HBS reference for which a low resorption rate was observed (remaining cement: 79.0 ± 6.9%; newly formed bone: 8.6 ± 4.8%). This study suggested that the particular microstructure, induced by the use of blood as the HBS liquid phase, favored quicker colonization of the implant and acceleration of its replacement by newly formed bone. For this reason, the HBS blood composite might be worth considering as a potentially suitable material for subchondroplasty. |
format | Online Article Text |
id | pubmed-10143268 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-101432682023-04-29 Calcium Phosphate Cements Combined with Blood as a Promising Tool for the Treatment of Bone Marrow Lesions Limelette, Maxence De Fourmestraux, Claire Despas, Christelle Lafragette, Audrey Veziers, Joelle Le Guennec, Yohan Touzot-Jourde, Gwenola Lefevre, François-Xavier Verron, Elise Bouler, Jean-Michel Bujoli, Bruno Gauthier, Olivier J Funct Biomater Article The solid phase of a commercial calcium phosphate (Graftys(®) HBS) was combined with ovine or human blood stabilized either with sodium citrate or sodium heparin. The presence of blood delayed the setting reaction of the cement by ca. 7–15 h, depending on the nature of the blood and blood stabilizer. This phenomenon was found to be directly related to the particle size of the HBS solid phase, since prolonged grinding of the latter resulted in a shortened setting time (10–30 min). Even though ca. 10 h were necessary for the HBS blood composite to harden, its cohesion right after injection was improved when compared to the HBS reference as well as its injectability. A fibrin-based material was gradually formed in the HBS blood composite to end-up, after ca. 100 h, with a dense 3D organic network present in the intergranular space, thus affecting the microstructure of the composite. Indeed, SEM analyses of polished cross-sections showed areas of low mineral density (over 10–20 µm) spread in the whole volume of the HBS blood composite. Most importantly, when the two cement formulations were injected in the tibial subchondral cancellous bone in a bone marrow lesion ovine model, quantitative SEM analyses showed a highly significant difference between the HBS reference versus its analogue combined with blood. After a 4-month implantation, histological analyses clearly showed that the HBS blood composite underwent high resorption (remaining cement: ca. 13.1 ± 7.3%) and new bone formation (newly formed bone: 41.8 ± 14.7%). This was in sharp contrast with the case of the HBS reference for which a low resorption rate was observed (remaining cement: 79.0 ± 6.9%; newly formed bone: 8.6 ± 4.8%). This study suggested that the particular microstructure, induced by the use of blood as the HBS liquid phase, favored quicker colonization of the implant and acceleration of its replacement by newly formed bone. For this reason, the HBS blood composite might be worth considering as a potentially suitable material for subchondroplasty. MDPI 2023-04-07 /pmc/articles/PMC10143268/ /pubmed/37103294 http://dx.doi.org/10.3390/jfb14040204 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Limelette, Maxence De Fourmestraux, Claire Despas, Christelle Lafragette, Audrey Veziers, Joelle Le Guennec, Yohan Touzot-Jourde, Gwenola Lefevre, François-Xavier Verron, Elise Bouler, Jean-Michel Bujoli, Bruno Gauthier, Olivier Calcium Phosphate Cements Combined with Blood as a Promising Tool for the Treatment of Bone Marrow Lesions |
title | Calcium Phosphate Cements Combined with Blood as a Promising Tool for the Treatment of Bone Marrow Lesions |
title_full | Calcium Phosphate Cements Combined with Blood as a Promising Tool for the Treatment of Bone Marrow Lesions |
title_fullStr | Calcium Phosphate Cements Combined with Blood as a Promising Tool for the Treatment of Bone Marrow Lesions |
title_full_unstemmed | Calcium Phosphate Cements Combined with Blood as a Promising Tool for the Treatment of Bone Marrow Lesions |
title_short | Calcium Phosphate Cements Combined with Blood as a Promising Tool for the Treatment of Bone Marrow Lesions |
title_sort | calcium phosphate cements combined with blood as a promising tool for the treatment of bone marrow lesions |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10143268/ https://www.ncbi.nlm.nih.gov/pubmed/37103294 http://dx.doi.org/10.3390/jfb14040204 |
work_keys_str_mv | AT limelettemaxence calciumphosphatecementscombinedwithbloodasapromisingtoolforthetreatmentofbonemarrowlesions AT defourmestrauxclaire calciumphosphatecementscombinedwithbloodasapromisingtoolforthetreatmentofbonemarrowlesions AT despaschristelle calciumphosphatecementscombinedwithbloodasapromisingtoolforthetreatmentofbonemarrowlesions AT lafragetteaudrey calciumphosphatecementscombinedwithbloodasapromisingtoolforthetreatmentofbonemarrowlesions AT veziersjoelle calciumphosphatecementscombinedwithbloodasapromisingtoolforthetreatmentofbonemarrowlesions AT leguennecyohan calciumphosphatecementscombinedwithbloodasapromisingtoolforthetreatmentofbonemarrowlesions AT touzotjourdegwenola calciumphosphatecementscombinedwithbloodasapromisingtoolforthetreatmentofbonemarrowlesions AT lefevrefrancoisxavier calciumphosphatecementscombinedwithbloodasapromisingtoolforthetreatmentofbonemarrowlesions AT verronelise calciumphosphatecementscombinedwithbloodasapromisingtoolforthetreatmentofbonemarrowlesions AT boulerjeanmichel calciumphosphatecementscombinedwithbloodasapromisingtoolforthetreatmentofbonemarrowlesions AT bujolibruno calciumphosphatecementscombinedwithbloodasapromisingtoolforthetreatmentofbonemarrowlesions AT gauthierolivier calciumphosphatecementscombinedwithbloodasapromisingtoolforthetreatmentofbonemarrowlesions |